Omnicell, Inc.
HealthcareNASDAQ:OMCL · NASDAQ Global Select
+$0.01 today
Vol 0.61M · Avg 0.56M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
0.2%
avg 3.2%
ROIC
0.1%
avg 0.7%
ROA
0.1%
avg 1.9%
Analysis
ROE is currently the strongest return metric at 0.2% versus its period average of 3.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Randall A. Lipps | Founder, Executive Chairman, President & Chief Executive Officer | $2.31M | — | 69 | $523,184.07 | 1.15% |
Nnamdi Njoku | Executive Vice President & Chief Operating Officer | $1.55M | — | 49 | $154,785.45 | 0.34% |
Corey J. Manley | Executive Vice President, Chief Legal & Administrative Officer and Corporate Secretary | $982,271.00 | — | 48 | $112,783.34 | 0.25% |
H. Baird Radford | Executive Vice President & Chief Financial Officer | $356,942.00 | — | 56 | $22,859.61 | 0.05% |
Perry A. Genova | Senior Vice President & Chief Technology Officer | — | — | — | — | — |
Stella Prefach | Senior VP & Chief Marketing Officer | — | — | — | — | — |
Sara Dalmasso | Senior Vice President & GM of International | — | — | 49 | $44,786.00 | 0.10% |
Tomer Stavitsky | Senior VP & Chief Corporate Development Officer | — | — | — | — | — |
Brian H. Nutt | Vice President, Chief Accounting Officer & Corporate Controller | — | — | 56 | $22,859.61 | 0.05% |
Dave Ford | Senior Vice President & Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$2.59M
Net Sentiment
$2.59M
Net selling
Most Active
Manley Corey J
8 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 10 sells worth $2.59M over the last 12 months. That adds up to net selling of $2.59M. Manley Corey J was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +21.4% | +8.1% (13yr)1 analysts |
| Revenue | N/A | N/A | +15.6% | +8.6% (13yr)2 analysts |
| Net Income | N/A | N/A | +23.9% | +10.0% (13yr)2 analysts |
| EBIT | N/A | N/A | +21.5% | -6.3% (13yr)2 analysts |
Analysis
Recent growth has been strongest in Net Income at +23.9% over three years. Forward estimates point to Net Income at +10.0% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
10x Genomics, Inc.
NASDAQ:TXG
$3.66B
Progyny, Inc.
NASDAQ:PGNY
$2.09B
Astrana Health, Inc.
NASDAQ:ASTH
$1.91B
UFP Technologies, Inc.
NASDAQ:UFPT
$1.82B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Omada Health
NASDAQ:OMDA
$1.02B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
SS Innovations International, Inc.
NASDAQ:SSII
$672.44M
Phreesia, Inc.
NYSE:PHR
$560.02M
Who manages OMCL?
Omnicell, Inc. (OMCL) lists 10 active executives. The top listed executive is Corey J. Manley, Executive Vice President, Chief Legal & Administrative Officer and Corporate Secretary.
Are OMCL insiders buying or selling?
Recent insider activity shows net selling of $19.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.